日本首款癌症恶病质药物Adlumiz效果怎么样？恶病质有什么症状？

Anamorelin is a ghrelin receptor agonist, which can simulate the ghrelin secreted by the gastrointestinal tract and improve the weight loss and loss of appetite in patients with cancer cachexia. It will be launched in Japan in April 2021, effectively improving the quality of life of patients. Today, let’s take a closer look at the effectiveness of Adlumiz, Japan’s first cancer cachexia drug. What are the symptoms of cachexia?

Anamorelin is mainly used to treat cancer cachexia in patients with gastric cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer and other malignant tumors. A trial in patients with non-small cell lung cancer (NSCLC) and a trial in patients with colorectal, gastric, and pancreatic cancer confirmed the drug's ability to increase weight, muscle mass, and appetite in patients with cancer cachexia. Anamorelin significantly improved the patient's weight and handgrip strength compared to placebo, and also significantly improved overall body weight and average scores on the Anorexia and Cache Scale.

So, what are the symptoms of cachexia? Cachexia, also known as cachexia, is characterized by symptoms such as extreme weight loss, complete bedridden, anemia, weakness, systemic failure and other syndromes. This disease is mostly caused by cancer and other serious chronic diseases, and cachexia associated with tumors is the most common. Cancer cachexia is a complex metabolic disorder syndrome that can lead to treatment intolerance, poor prognosis, and even premature death in cancer patients. The launch of Anamorelin brings hope to patients and becomes an important milestone in improving patients' quality of life. Patients who need this medicine can contact Medical Companion Travel to obtain it, which is guaranteed to be genuine.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: